Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 4 | 2013 | 451 | 0.890 |
Why?
|
| Interferons | 3 | 2013 | 291 | 0.840 |
Why?
|
| Ribavirin | 3 | 2010 | 178 | 0.730 |
Why?
|
| Antiviral Agents | 5 | 2021 | 1230 | 0.690 |
Why?
|
| Kupffer Cells | 1 | 2019 | 42 | 0.680 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2019 | 56 | 0.640 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 193 | 0.590 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 68 | 0.570 |
Why?
|
| Liver Transplantation | 4 | 2017 | 1112 | 0.550 |
Why?
|
| Liver Cirrhosis | 5 | 2020 | 941 | 0.510 |
Why?
|
| Everolimus | 1 | 2017 | 415 | 0.490 |
Why?
|
| Hepatitis B | 2 | 2021 | 258 | 0.450 |
Why?
|
| Graft Survival | 1 | 2017 | 1062 | 0.450 |
Why?
|
| Graft Rejection | 1 | 2017 | 834 | 0.420 |
Why?
|
| Liver | 2 | 2019 | 2961 | 0.410 |
Why?
|
| Kidney Diseases | 1 | 2017 | 691 | 0.390 |
Why?
|
| Retinal Diseases | 1 | 2013 | 179 | 0.390 |
Why?
|
| Lypressin | 1 | 2010 | 11 | 0.370 |
Why?
|
| Hepatorenal Syndrome | 1 | 2010 | 19 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 2027 | 0.350 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 151 | 0.340 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2007 | 19 | 0.310 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 217 | 0.310 |
Why?
|
| Sarcoidosis | 1 | 2008 | 112 | 0.310 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 107 | 0.290 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 1375 | 0.290 |
Why?
|
| Fatty Liver | 1 | 2008 | 235 | 0.290 |
Why?
|
| Fibrosis | 1 | 2009 | 793 | 0.280 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 615 | 0.240 |
Why?
|
| Interferon-alpha | 1 | 2007 | 889 | 0.230 |
Why?
|
| Liver Diseases | 1 | 2008 | 574 | 0.230 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 24 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2017 | 524 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 349 | 0.150 |
Why?
|
| Lip Neoplasms | 1 | 2017 | 18 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4557 | 0.150 |
Why?
|
| Ethanol | 1 | 2019 | 264 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 602 | 0.140 |
Why?
|
| Liver Failure | 1 | 2017 | 140 | 0.140 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 192 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 2594 | 0.130 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2020 | 421 | 0.130 |
Why?
|
| Metabolomics | 1 | 2017 | 478 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2017 | 173 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 2315 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 1085 | 0.110 |
Why?
|
| Humans | 17 | 2021 | 261506 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 698 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 181 | 0.110 |
Why?
|
| Sirolimus | 1 | 2017 | 814 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 1171 | 0.100 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 1991 | 11 | 0.100 |
Why?
|
| Jejunal Neoplasms | 1 | 1991 | 34 | 0.100 |
Why?
|
| Jejunal Diseases | 1 | 1991 | 25 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1900 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 580 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4320 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 907 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2009 | 84 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2014 | 32848 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 227 | 0.080 |
Why?
|
| Azathioprine | 1 | 2008 | 66 | 0.080 |
Why?
|
| Biopsy | 3 | 2017 | 3443 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 2146 | 0.080 |
Why?
|
| Prednisolone | 1 | 2008 | 123 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2014 | 620 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 2083 | 0.080 |
Why?
|
| Dipeptidases | 1 | 2007 | 16 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1249 | 0.080 |
Why?
|
| Filgrastim | 1 | 2007 | 191 | 0.080 |
Why?
|
| Creatinine | 1 | 2010 | 531 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2009 | 694 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2010 | 6869 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 8865 | 0.070 |
Why?
|
| Biomarkers | 3 | 2020 | 5047 | 0.070 |
Why?
|
| Time Factors | 2 | 2010 | 12926 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 3251 | 0.070 |
Why?
|
| Male | 9 | 2020 | 123000 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 630 | 0.060 |
Why?
|
| Risk Factors | 2 | 2013 | 17523 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 749 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3719 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2330 | 0.060 |
Why?
|
| Middle Aged | 6 | 2020 | 86204 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 5673 | 0.060 |
Why?
|
| Prognosis | 2 | 2017 | 21713 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 7551 | 0.050 |
Why?
|
| Adult | 6 | 2020 | 77950 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 2927 | 0.050 |
Why?
|
| Recurrence | 1 | 2010 | 4758 | 0.050 |
Why?
|
| Dermatologists | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2021 | 51 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 110 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2008 | 2203 | 0.050 |
Why?
|
| Melanoma | 1 | 2017 | 5317 | 0.050 |
Why?
|
| Female | 6 | 2020 | 141928 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 148 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.030 |
Why?
|
| Steroids | 1 | 2017 | 356 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 21445 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 2992 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 11538 | 0.030 |
Why?
|
| Aged | 4 | 2017 | 70117 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 717 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 7789 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6009 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 1991 | 310 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1991 | 375 | 0.020 |
Why?
|
| Ligation | 1 | 2007 | 193 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2007 | 113 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 37905 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2007 | 562 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6682 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 980 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 1546 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 14889 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 13658 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 6086 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 31252 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 59536 | 0.000 |
Why?
|